Streamlined Structures of Human Integral Membrane Proteins at Atomic Resolution
Project Number1DP2OD008591-01
Contact PI/Project LeaderALLER, STEPHEN G
Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
DESCRIPTION (Provided by the applicant)
Abstract: Streamlined Structures of Human Integral Membrane Proteins at Atomic Resolution About 35% of the human genome encodes integral membrane proteins (IMPs) and one-third of approved drugs target this class. While human IMPs are amenable to straightforward biochemistry, structural studies are nearly intractable as evidenced by the paucity of human IMP structures available. To date, only five human IMP structures have been solved to truly atomic resolution (< 3.0 ¿). None of the human IMP structures represent transporters, likely due to the extreme flexibility from alternating access mechanisms impeding crystallography. Sharp resolution of IMPs in multiple conformations is a prerequisite for understanding the full mechanism of transport proteins, the role of amino acids in substrate recognition, drug binding, inter-domain communication and for accurate structure-based drug design. Structure-determination of human IMPs lags decades behind the determination of soluble protein structures. We plan to accelerate the process and simultaneously provide human IMP structures in multiple conformations at atomic resolution. Our innovative strategy utilizes the screening of a synthetic antibody library to rapidly identify high- affinity Fabs (SynFabs) that will serve as scaffolds for crystallography. The versatile SynFab library can recognize virtually limitless numbers of antigens, will trap human IMPs in multiple conformations and will universalize the structure determination process using molecular replacement methods. We have engineered molecular chaperones to enable the production of the most difficult human IMPs in folded mature form using a low-cost yeast expression system. Our innovative and comprehensive strategy will accelerate structure determination of human IMPs by years, shedding light on the mechanisms of serious diseases including Cystic Fibrosis (CF), diabetes, cancer, polycystic kidney disease, inflammation, AIDS and multi-drug resistance (MDR).
Public Health Relevance: Many diseases are directly caused by a major class of proteins called integral membrane proteins (IMPs). Obtaining three-dimensional structures of human IMPs has been far too costly and time-consuming for effective drug design or the computational prediction of drug absorption, permeation of drug barriers, and multi-drug resistance. We employ a new strategy to determine structures of human IMPs at highthroughput to integrate these computational approaches and accelerate drug discovery.
Public Health Relevance Statement
Public Health Relevancy Statement
Many diseases are directly caused by a major class of proteins called integral membrane proteins (IMPs).
Obtaining three-dimensional structures of human IMPs has been far too costly and time-consuming for
effective drug design or the computational prediction of drug absorption, permeation of drug barriers, and
multi-drug resistance. We employ a new strategy to determine structures of human IMPs at high-
throughput to integrate these computational approaches and accelerate drug discovery.
No Sub Projects information available for 1DP2OD008591-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1DP2OD008591-01
Patents
No Patents information available for 1DP2OD008591-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1DP2OD008591-01
Clinical Studies
No Clinical Studies information available for 1DP2OD008591-01
News and More
Related News Releases
No news release information available for 1DP2OD008591-01
History
No Historical information available for 1DP2OD008591-01
Similar Projects
No Similar Projects information available for 1DP2OD008591-01